AlphaCrest Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

AlphaCrest Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,272	Closed	-$1.14M	–	989
2022 Q3	$1.14M	Sell	10,272 -7,512	-42%	-$757K	0.07%	529
2022 Q2	$1.33M	Sell	17,784 -7,283	-29%	-$536K	0.06%	525
2022 Q1	$1.96M	Buy	25,067 +16,196	+183%	+$1.24M	0.11%	251
2021 Q4	$799K	Buy	+8,871	New	+$758K	0.03%	906
2021 Q3	–	Sell	-15,741	Closed	-$1.22M	–	1374
2021 Q2	$1.22M	Sell	15,741 -4,447	-22%	-$337K	0.05%	565
2021 Q1	$1.5M	Buy	20,188 +18,883	+1,447%	+$1.74M	0.08%	356
2020 Q4	$222K	Sell	1,305 -1,252	-49%	-$186K	0.02%	1037
2020 Q3	$359K	Sell	2,557 -1,382	-35%	-$210K	0.04%	777
2020 Q2	$632K	Buy	+3,939	New	+$536K	0.11%	292
2020 Q1	–	Sell	-4,569	Closed	-$590K	–	1261
2019 Q4	$590K	Sell	4,569 -1,580	-26%	-$159K	0.05%	678
2019 Q3	$463K	Buy	+6,149	New	+$726K	0.03%	947

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AlphaCrest Capital Management's SRPT Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2022, closing a stake of 10,272 shares — an estimated $1.14M sold.

AlphaCrest Capital Management first reported a position in SRPT in Q3 2019 and held it in 11 quarters. The position peaked at $1.96M in Q1 2022. 412 funds tracked by Wall St. Rank hold SRPT as of Q4 2022.

AlphaCrest Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 10,272 Sarepta Therapeutics shares in Q4 2022, an estimated $1.14M.
AlphaCrest Capital Management first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 11 quarters.
AlphaCrest Capital Management's Sarepta Therapeutics position peaked at $1.96M in Q1 2022.
412 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.